| Jorge L Cruz, MD | |
|
2104 Gause Blvd W, Ste. A, Slidell, LA 70460-4130 | |
| (985) 643-4512 | |
| (985) 643-4513 |
| Full Name | Jorge L Cruz |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 2104 Gause Blvd W, Slidell, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891989380 | NPI | - | NPPES |
| 1508012 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | MD.201422 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| E. M. Dimitri, D.o. Pmc. | 4284722059 | 17 |
News Archive
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
The troubled Cover Oregon insurance exchange unveiled its long-awaited beta website to mixed reviews Tuesday. Meanwhile, Humana announced it will waive fees for enrollees who bought plans on the Mississippi exchange who see a doctor by the end of June for a non-preventive visit. Also, Republicans probe state websites which are still having major problems.
› Verified 2 days ago
| Entity Name | E. M. Dimitri, D.o. Pmc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821285974 PECOS PAC ID: 4284722059 Enrollment ID: O20071116000378 |
News Archive
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
The troubled Cover Oregon insurance exchange unveiled its long-awaited beta website to mixed reviews Tuesday. Meanwhile, Humana announced it will waive fees for enrollees who bought plans on the Mississippi exchange who see a doctor by the end of June for a non-preventive visit. Also, Republicans probe state websites which are still having major problems.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jorge L Cruz, MD 2104 Gause Blvd W, Ste. A, Slidell, LA 70460-4130 Ph: (985) 643-4512 | Jorge L Cruz, MD 2104 Gause Blvd W, Ste. A, Slidell, LA 70460-4130 Ph: (985) 643-4512 |
News Archive
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment.
The enzyme that makes fireflies glow is lighting up the scientific path toward a long-sought new medical imaging agent to better monitor treatment with heparin, the blood thinner that millions of people take to prevent or treat blood clots, scientists are reporting. Their study appears in the ACS' monthly journal Bioconjugate Chemistry.
The troubled Cover Oregon insurance exchange unveiled its long-awaited beta website to mixed reviews Tuesday. Meanwhile, Humana announced it will waive fees for enrollees who bought plans on the Mississippi exchange who see a doctor by the end of June for a non-preventive visit. Also, Republicans probe state websites which are still having major problems.
› Verified 2 days ago
Dr. Joel E Perdomo, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 2104 Gause Blvd W, Suitea, Slidell, LA 70460 Phone: 985-643-4575 Fax: 985-643-4513 | |
Dr. Kevin Lindsey, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 122 Weatherly Cv, Slidell, LA 70458 Phone: 985-661-9734 | |
Dr. Thomas J Orgeron, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 2104 Gause Blvd W, Ste. A, Slidell, LA 70460 Phone: 985-643-4575 Fax: 985-643-4513 | |
Wadia Hamed, General Practice Medicare: Medicare Enrolled Practice Location: 1001 Gause Blvd, Slidell, LA 70458 Phone: 985-280-8743 |